There’s always something new and exciting going on at INTERPHEX. Check out our announcements for the very latest news.

Share This:

Optel Vision Launches Its Latest Innovation at INTERPHEX


-The CountSafe™ with Automatic Ejection, a cutting-edge technology for inspecting and Automatically rejecting faulty products-

NEW YORK, NY; APRIL 17, 2015 – International Pharmaceutical Expo (INTERPHEX), the premier pharmaceutical and biopharmaceutical event dedicated to innovation, technology and knowledge, and sponsored by the Parenteral Drug Association (PDA), today announced that Optel Vision will launch its latest cutting-edge innovation, The CountSafe™ with Automatic Ejection, at INTERPHEX, April 21-23, 2015 at the Javits Center in New York.

Optel ProductDemonstrating for the first time at INTERPHEX 2015, booth #2353, the Automatic Ejection for Electronic Counters is a two-axis linear robot that can be adapted and integrated to any Electronic Counter on the market. Combined with Optel Vision’s CountSafe™ inspection system, the ejector is a tool-less device that can reject any kind of defect: wrong shape, wrong color, wrong size and broken product or rogue. Products get rejected through a vacuum system, which is attached to a closed bin that is equipped with a pre-separator collector and a HEPA filter, thus preventing any substance or dust to escape.

“Bringing this innovation to the market will be a relief for our customers, who will benefit from 100% automatic ejection of bad products from their production line. The inspection of our CountSafe™, combined with the accuracy of the ejector, guarantees 100% rejection of default products, therefore avoiding rework from the operator,” said Louis Roy, President, Optel Vision.

On a four-vibratory feeding tray system of 28 inches in width, it takes less than 5 seconds for the ejector to stop the inspection, remove the wrong product, confirm the ejection and restart the inspection. This innovation ensures the highest production throughput possible.  By avoiding downtime and while removing default products in a controlled environment, line efficiency is improved.

“The ejector speed and the precision of rejection is a huge gain of time, compared to having an operator interacting with the system and removing the wrong product manually from the production line,” said Jim White, Product Manager, Optel Vision.

White continued, “Optel Vision is committed to innovation and answering the challenging demands of its customers. We are proud to bring new innovative solutions to the packaging industry for pharmaceutical companies.”

See the CountSafe™ in action. View the other technologies that Optel Vision is bringing to the Show.

About Optel Vision
Optel Vision specializes in the development and manufacture of innovative vision inspection and Track & Trace solution for the pharmaceutical industry. Every day, the company ensures the quality of billions of products in over twenty countries, including Canada, the United States, all across Europe, China and India. The technologies developed by Optel Vision allows the detection of errors in manufacturing and packaging on production lines of major pharmaceutical manufacturers, reducing the risks to public health.”

INTERPHEX (International Pharmaceutical Expo), sponsored by Parenteral Drug Association (PDA) is the single source for complete biopharmaceutical manufacturing solutions to safely and cost effectively process all dosage forms for life-enhancing drugs. It brings over 12,000 global pharmaceutical and biotechnology professionals together with 600+ suppliers via 300,000sf of event space through a unique combination of exhibition, education, workshops, partnering opportunities, and networking events. INTERPHEX offers annual national and international industry events and educational opportunities around the world.  For more information, visit and follow INTERPHEX on Facebook, LinkedIn and Twitter (@INTERPHEX.) IPX Blog continues the learning beyond the show floor and INTERPHEX Connector is the new twice-weekly email industry insight and news briefing.

About PDA
The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its nearly 10,000 members worldwide.


We use cookies to operate this website and to improve its usability. Full details of what cookies are, why we use them and how you can manage them can be found by reading our Privacy & Cookies page. Please note that by using this site you are consenting to the use of cookies.